Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Aseptic meningitis following AZD1222 COVID-19 vaccination

Arefah Zavari a, Negin Mahmoudi Hamidabad a,b, *, Morteza Hassanzadeh a

a School of Medicine, Department of Internal Medicine, Rasoul-E-Akrham Hospital, Iran University of Medical Sciences, Tehran, Iran
b School of Medicine, Department of Neurology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran

Article history:
Received 14 December 2021
Accepted 14 December 2021

Keywords:
COVID-19 vaccine
Aseptic meningitis
AZD1222

1. Introduction

COVID-19 vaccination has been proven to reduce the risk of serious illness and death [1]. Although the safety of vaccines is monitored during clinical trials, some rare side effects might not be identified until they are used for vaccination of the general population. In phase 2 and 3 of the AZD1222 COVID-19 vaccine trials, good immunogenicity was reported, and no serious side effects were seen with the vaccine [2].

Aseptic meningitis is defined as meningoeal inflammation and pleocytosis (≥5 cells/mm3) of cerebrospinal fluid (CSF) in the absence of infection [3]. It is usually self-limited and resolves within a week [4]. Aseptic meningitis has previously been reported with mumps, varicella, and influenza vaccines [5-7], but data regarding its incidence with COVID-19 vaccination is scarce. There is one report of aseptic meningitis following the BNT162b2 mRNA vaccine [8].

Herein, we report a case of aseptic meningitis following the AZD1222 vaccine.

2. Case presentation

A 26-year-old otherwise healthy female healthcare worker, with no family history of autoimmune diseases, received the first dose of AZD1222 vaccine on April 20th, 2021. She developed low-grade fever a few hours after receiving the shot, which was followed by a frontal tension type headache, and photophobia the next morning. There was no neck stiffness in physical examination; Kernig and Brudzinsky signs were negative, and the optic disc appeared normal. No cranial nerve involvement was detected during the physical examination. She was put on acetaminophen (500 mg TDS), and Ibuprofen (400 mg BID) for symptom relief. After two days, the symptoms did not resolve and the headache worsened. The patient reported her pain score as 8 out of 10, along with nausea, vomiting, and myalgia. Results of two polymerase chain reaction (PCR) tests for Covid-19 were negative. Blood protein, reported normal. Intravenous fluids and ketorolac were administered which resulted in some relief of symptoms for 4 h.

After that, the symptoms recurred and the patient reported a severe headache with the pain scored as 9 out of 10. With worsening headache and photophobia, magnetic resonance imaging (MRI), magnetic resonance angiography (MRA), and magnetic resonance venography (MRV) of the brain were requested and all three studies were normal. A computed tomography (CT) scan of the chest, was performed six days after the first symptoms and showed no sign of Covid-19 infection. At this stage, a lumbar puncture was performed, which showed 5 lymphocytes/mm3 in the cerebrospinal fluid (CSF) and slightly increased protein (54 mg/dl). The CSF/serum glucose ratio was 0.7. The result of the CSF viral panel was negative. The titer of serum antinuclear antibody was normal at 1/80. The patient was diagnosed with aseptic meningitis and was put on prednisolone 20 mg daily, for three days, which then was tapered during the next 9 days. Shortly after treatment, the headache fully resolved and the patient remained symptom-free. Three months later, she received the second dose of the vaccine and just had some mild constitutional symptoms which resolved spontaneously in three days.

* Corresponding author at: Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
E-mail addresses: zavari.bd@gmail.com (A. Zavari), Negin.Mahmoodi65@gmail.com (N.M. Hamidabad), Hassanzadeh.m@iums.ac.ir (M. Hassanzadeh).

https://doi.org/10.1016/j.ajem.2021.12.035
0735-6757/© 2021 Elsevier Inc. All rights reserved.
3. Discussion

We reported a case of severe headache after receiving the first dose of the AZD1222 vaccine. All workouts were negative and with the CFSE evaluation, the diagnosis of vaccine-associated aseptic meningitis was made.

Vaccines appear to be safe and life-saving. There have been reports of some serious neurologic adverse effects, such as demyelinating syndromes associated with the administration of viral vaccines in the past; but epidemiological studies have revealed no increased risk of these adverse effects with vaccination [9]. AZD1222 vaccine is among many COVID-19 vaccines currently being used around the world. Although phase 2/3 of its clinical trial found no serious adverse effects with vaccine administration, some serious adverse effects have been reported. Hematologic adverse effects of AZD1222 include cerebral venous thrombosis [10], and vaccine-induced thrombotic thrombocytopenia (VITT) [11]. Some serious neurologic adverse effects have also been reported which include Guillain Barre Syndrome [12], and acute transverse myelitis [13].

Aseptic meningitis is a term including all causes of meningeal inflammation with negative CSF cultures. It has a mild course and resolves spontaneously during a week [4]. Viruses are the most common cause of infectious aseptic meningitis. Non-infectious etiologies include neoplastic and drug-induced etiologies (most commonly reported with non-steroidal anti-inflammatory drugs), as well as meningeal involvement in connective tissue diseases (e.g. systemic lupus erythematosus) [14]. Also, aseptic meningitis has been reported following certain vaccines such as measles, mumps, and rubella vaccine [15], varicella-zoster vaccine, yellow fever vaccine, rabies vaccine, pertussis vaccine, and influenza vaccine [6,7].

There has been no report of aseptic meningitis with the AZD1222 vaccine yet. Regarding COVID-19 vaccines, there is one recent report of COVID-19 mRNA vaccine causing aseptic meningitis [8]. The true mechanism by which vaccines cause aseptic meningitis is unknown. The AZD1222 is a viral vector vaccine based on the chimpanzee adenovirus Y25 (ChAdOx1). To make immunity, vaccines interact with the immune system; which leads to the expression of the pro-inflammatory cytokine Y25 (ChAdOx1). To make immunity, vaccines interact with the immune system, this neuroinflammation following vaccination is unknown. The other case of aseptic meningitis with mRNA Covid-19 vaccine occurred shortly after the administration of prednisolone. Although the exact mechanism of meningeal inflammation following vaccination is unclear, these two cases suggest an immune-mediated mechanism for vaccine-induced aseptic meningitis. It might be helpful to monitor these patients for autoimmune diseases in the future.

Funding

This case report has received no funding.

CRediT authorship contribution statement

Arefeh Zavari: Writing – original draft. Negin Mahmoudi Hamidabad: Writing – review & editing, Conceptualization, Writing – original draft. Morteza Hassanzadeh: Conceptualization, Writing – review & editing.

Declaration of Competing Interest

The authors declare no conflict of interests.

References

[1] Moghadas SM, et al. The impact of vaccination on COVID-19 outbreaks in the United States. medRxiv: the preprint server for health sciences; 2021 p. 2021.01.27.20240051.
[2] Ramasamy MN, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet (London, England). 2021;396(10267):1997–99.
[3] Nigrovic LE. Chapter 119 - Aseptic meningitis. In: Dulac O, Lassonde M, Sarnat HB, editors. Handbook of clinical neurology. Elsevier; 2013. p. 1153–6.
[4] Logan SA, MacMahon E. Viral meningitis. Bmj. 2008;336(7634):36–40.
[5] Bonnet MC, et al. Mumps vaccine virus strains and aseptic meningitis. Vaccine. 2006;24(49–50):7037–45.
[6] Dourado I, et al. Outbreak of aseptic meningitis associated with mass vaccination with a urabe-containing measles-mumps-rubella vaccine: implications for immunization programs. Am J Epidemiol. 2000;151(5):524–30.
[7] Jorquera LA, et al. Aseptic meningitis due to mumps vaccine. Case report and review of the literature. Rev Chilena Infectol. 2020;37(6):769–74.
[8] Saito K, et al. Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine. Neurol Sci. 2021:1–3.
[9] Principi N, Esposito S. Do vaccines have a role as a cause of autoimmune neurological syndromes? Front Public Health. 2020;8:361.
[10] Wu Y, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2021.51:153786.
[11] Collantes MEV, et al. Neurological manifestations in COVID-19 infection: a systematic review and meta-analysis. Can J Neurol Sci. 2021;48(1):66–76.